Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer

Table 3

Trials using Anti-EGFR mABs with chemotherapy in chemoresistant mCRC selected by KRAS status.

Trial (author)	Phase	KRAS	Protocol	Number enrolled	Results		HR (95% CI)	𝑃 value
					PFS	OS
PICCOLO (Seymour et al.) [18]	III	WT; WT	Irinotecan + panitumumab; Irinotecan	Total number of patients = 324		10.4 mos.; 10.5 mos.	OS: 0.91 (0.73–1.14)	0.44
Study 181 (Sobrero et al.) [19]	III	WT	FOFIRI + panitumumab; FOLFIRI	303; 294	6.7 mos.; 4.9 mos.	14.5 mos.; 12.5 mos.	PFS: 0.82 (0.69–0.97); OS: 0.92 (0.78–1.10)	0.023; 0.366
		MUT	FOFIRI + panitumumab; FOLFIRI	238; 248	5.3 mos.; 5.4 mos.	11.8 mos.; 11.1 mos.	PFS: 0.95 (0.78–1.14); OS: 0.93 (0.77–1.13)	0.561; 0.482

WT: wild type, MUT: mutated, PFS: progression free survival, and OS: overall survival.